Legato Capital Management LLC Invests $972,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legato Capital Management LLC acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,955 shares of the medical equipment provider's stock, valued at approximately $972,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. State of Michigan Retirement System boosted its stake in Lantheus by 0.6% in the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock worth $1,620,000 after purchasing an additional 100 shares in the last quarter. Signaturefd LLC raised its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 116 shares during the last quarter. Avantax Advisory Services Inc. raised its position in shares of Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares during the last quarter. Foundry Partners LLC raised its position in shares of Lantheus by 4.5% during the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after acquiring an additional 133 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock worth $653,000 after acquiring an additional 139 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

LNTH has been the subject of a number of recent research reports. Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. B. Riley dropped their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, William Blair restated a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $131.20.

Lantheus Trading Up 2.8%

NASDAQ LNTH traded up $2.00 on Friday, reaching $72.93. The company had a trading volume of 615,452 shares, compared to its average volume of 1,083,256. The stock's 50 day moving average is $78.06 and its 200-day moving average is $88.72. The stock has a market cap of $5.05 billion, a price-to-earnings ratio of 20.72 and a beta of 0.12. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 52 week low of $69.12 and a 52 week high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same quarter last year, the company earned $1.69 earnings per share. The firm's revenue was up .8% compared to the same quarter last year. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.